Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Catalyst Pharma ( (CPRX) ) is now available.
On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors of Catalyst Pharmaceuticals, announced he would not seek reelection at the 2025 annual stockholders’ meeting, concluding his long-standing service on the Board since 2004. His decision was not due to any disagreement with the company. The company plans to hire a recruitment firm to find a new director, marking a significant transition in its leadership structure.
More about Catalyst Pharma
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company primarily focused on in-licensing, developing, and commercializing novel medications for patients with rare diseases.
YTD Price Performance: 4.60%
Average Trading Volume: 1,124,517
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.68B
For detailed information about CPRX stock, go to TipRanks’ Stock Analysis page.
